Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Case Medical Research ◽

10.31525/ct1-nct04158245 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Faculty Opinions recommendation of Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717999366.793474668 ◽

2013 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Antitumour Activity ◽

Abiraterone Acetate ◽

A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer

Current Pharmaceutical Analysis ◽

10.2174/1573412913666170213152002 ◽

2018 ◽

Vol 14 (3) ◽

pp. 233-238 ◽

Cited By ~ 1

Author(s):

Juana Rodriguez ◽

Gregorio Castaneda ◽

Isabel Lizcano ◽

Jose C. Villa

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Fluorescence Method ◽

Serum Samples ◽

Castration Resistant ◽

Urine And Serum

Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2021.1888704 ◽

2021 ◽

Vol 37 (4) ◽

pp. 635-642

Author(s):

Stephen J. Freedland ◽

Sophia Li ◽

Dominic Pilon ◽

Rachel H. Bhak ◽

Sahil Narkhede ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Psa Progression

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Molecular Oncology ◽

10.1002/1878-0261.12933 ◽

2021 ◽

Author(s):

E. Boerrigter ◽

G.E. Benoist ◽

I.M. van Oort ◽

G.W. Verhaegh ◽

O. van Hooij ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Marker ◽

Liquid Biopsy ◽

Progression Free Survival ◽

Abiraterone Acetate ◽

First Line ◽

Free Survival ◽

Prednisone Treatment ◽

Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate

Prostate Cancer and Prostatic Diseases ◽

10.1038/s41391-021-00336-1 ◽

2021 ◽

Author(s):

Rosario F. Di Stefano ◽

Marcello Tucci ◽

Fabio Turco ◽

Alessandro Samuelly ◽

Maristella Bungaro ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Prognostic Role ◽

Castration Resistant ◽

Duration Of Response

A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyv070 ◽

2015 ◽

Vol 45 (8) ◽

pp. 774-779 ◽

Cited By ~ 4

Author(s):

Yujiro Ueda ◽

Nobuaki Matsubara ◽

Itsuhiro Takizawa ◽

Tsutomu Nishiyama ◽

Ken-ichi Tabata ◽

...

Keyword(s):

Prostate Cancer ◽

Retrospective Analysis ◽

Japanese Patients ◽

Abiraterone Acetate ◽

Sequential Treatment ◽

Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)

Annals of Oncology ◽

10.1093/annonc/mdy284.019 ◽

2018 ◽

Vol 29 ◽

pp. viii280

Author(s):

C. Ohlmann ◽

Z. Roger ◽

C. Rüssel ◽

E. Hellmis ◽

H. Suttmann ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Lhrh Therapy

713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL

The Journal of Urology ◽

10.1016/j.juro.2013.02.272 ◽

2013 ◽

Vol 189 (4S) ◽

Cited By ~ 1

Author(s):

Fred Saad ◽

Neal D Shore ◽

Hendrik Van Poppel ◽

Dana Rathkopf ◽

Matthew R. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Interim Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Prior Chemotherapy ◽